Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
Int J Cancer
    August 2024
  1. BUI TT, Park E, Kang HY, Oh JK, et al
    Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case-control study in South Korea.
    Int J Cancer. 2024;155:654-665.
    >> Share

    June 2024
  2. ZHAO L, Zhang X, Birmann BM, Danford CJ, et al
    Pre-diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population-based cohort studies from the United States and the United Kingdom.
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35054.
    >> Share

  3. KARA-ALI GH, Cano L, Dion S, Imerzoukene G, et al
    Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
    Int J Cancer. 2024;154:1999-2013.
    >> Share

    May 2024
  4. PUPACDI B, Loffredo CA, Budhu A, Rabibhadana S, et al
    The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand.
    Int J Cancer. 2024 May 18. doi: 10.1002/ijc.35034.
    >> Share

  5. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
    N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
    Int J Cancer. 2024;154:1857-1868.
    >> Share

    February 2024
  6. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
    Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
    Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
    >> Share

  7. YU Z, Bai X, Zhou R, Ruan G, et al
    Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019.
    Int J Cancer. 2024;154:615-625.
    >> Share

  8. XU FQ, Xu QY, Zhu ZJ, Jin L, et al
    Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study.
    Int J Cancer. 2024;154:530-537.
    >> Share

  9. JIANG L, Zhao N, Xu M, Pei J, et al
    Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis.
    Int J Cancer. 2024;154:465-476.
    >> Share

  10. BARUPAL DK, Ramos ML, Florio AA, Wheeler WA, et al
    Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.
    Int J Cancer. 2024;154:454-464.
    >> Share

    January 2024
  11. ZHAO G, Shi X, Zhang L, Liang H, et al
    Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
    >> Share

  12. KIM MN, Zhang X, Ahn SH
    Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
    >> Share

    November 2023
  13. ROSSARI F, Tada T, Suda G, Shimose S, et al
    alpha-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Int J Cancer. 2023 Nov 23. doi: 10.1002/ijc.34799.
    >> Share

    October 2023
  14. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    >> Share

  15. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    >> Share

    August 2023
  16. HA Y, Lim J, Chon YE, Kim MN, et al
    Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34704.
    >> Share

    July 2023
  17. SHANG Y, Morioka T, Daino K, Nakayama T, et al
    Ionizing radiation promotes, whereas calorie restriction suppresses, NASH and hepatocellular carcinoma in mice.
    Int J Cancer. 2023 Jul 17. doi: 10.1002/ijc.34651.
    >> Share

  18. KIM MN, Han K, Yoo J, Hwang SG, et al
    Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
    >> Share

    March 2023
  19. HEMMINKI K, Sundquist K, Sundquist J, Forsti A, et al
    Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers.
    Int J Cancer. 2023;152:1107-1114.
    >> Share

  20. LI ZY, Tan YT, Liu DK, Gao LF, et al
    Cumulative consumption of tea is associated with lower risk of liver cancer: Updated results from the Shanghai Women's Health Study.
    Int J Cancer. 2023;152:1115-1123.
    >> Share

  21. VANDERBORGHT B, De Muynck K, Gijbels E, Lefere S, et al
    Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34505.
    >> Share

  22. PETRICK JL, Florio AA, Zen J, Wang Y, et al
    Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV Cohort Studies.
    Int J Cancer. 2023 Mar 6. doi: 10.1002/ijc.34492.
    >> Share

    February 2023
  23. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    >> Share

    August 2022
  24. ZHANG P, Ono A, Fujii Y, Hayes CN, et al
    The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34247.
    >> Share

    July 2022
  25. HANG D, Yang X, Lu J, Shen C, et al
    Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: A prospective study in two Chinese cohorts.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34229.
    >> Share

  26. COMMANDER SJ, Cerullo M, Arjunji N, Leraas HJ, et al
    Improved Survival and Higher Rates of Surgical Resection Associated with Hepatocellular Carcinoma in Children as Compared to Young Adults.
    Int J Cancer. 2022 Jul 16. doi: 10.1002/ijc.34215.
    >> Share

  27. WEN Q, Chan KH, Shi K, Lv J, et al
    Tobacco smoking and solid fuels for cooking and risk of liver cancer: A prospective cohort study of 0.5 million Chinese adults.
    Int J Cancer. 2022;151:181-190.
    >> Share

  28. FU P, Gong B, Li H, Luo Q, et al
    Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34201.
    >> Share

    June 2022
  29. NIGER M, Nichetti F, Casadei-Gardini A, Rizzato MD, et al
    Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34182.
    >> Share

  30. ZHENG G, Bouamar H, Cserhati M, Zeballos CR, et al
    Integrin alpha 6 (ITGA6) is upregulated and drives hepatocellular carcinoma progression through integrin alpha6beta4 complex.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34146.
    >> Share

    May 2022
  31. WU H, Zheng X, Pan T, Yang X, et al
    Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34118.
    >> Share

  32. YUN J, Kim YS, Heo MJ, Kim MJ, et al
    ERalpha inhibits mesenchymal and amoeboidal movement of liver cancer cell via Galpha12.
    Int J Cancer. 2022;150:1690-1705.
    >> Share

  33. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    >> Share

    April 2022
  34. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    >> Share

  35. LIAO W, Du J, Wang Z, Feng Q, et al
    The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34040.
    >> Share

  36. HEMMINKI K, Tichanek F, Forsti A, Hemminki O, et al
    Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34031.
    >> Share

    March 2022
  37. VAZ J, Midlov P, Eilard MS, Eriksson B, et al
    Targeting population groups with heavier burden of hepatocellular carcinoma incidence: a nationwide descriptive epidemiological study in Sweden.
    Int J Cancer. 2022 Mar 7. doi: 10.1002/ijc.33993.
    >> Share

    February 2022
  38. SEFRIOUI D, Verdier V, Savoye-Collet C, Beaussire L, et al
    Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
    Int J Cancer. 2022;150:532-541.
    >> Share

    December 2021
  39. KIM MN, Han K, Yoo J, Ha Y, et al
    Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33920.
    >> Share

  40. TANAKA H, Horioka K, Hasebe T, Sawada K, et al
    Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33915.
    >> Share

  41. RUTHERFORD MJ, Arnold M, Bardot A, Ferlay J, et al
    Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
    Int J Cancer. 2021;149:2020-2031.
    >> Share

  42. RIDDER DA, Weinmann A, Schindeldecker M, Urbansky LL, et al
    Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma.
    Int J Cancer. 2021 Dec 11. doi: 10.1002/ijc.33898.
    >> Share

  43. SO R, Chen J, Mehta AJ, Liu S, et al
    Long-term exposure to air pollution and liver cancer incidence in six European cohorts.
    Int J Cancer. 2021;149:1887-1897.
    >> Share

    November 2021
  44. STEPIEN M, Lopez-Nogueroles M, Lahoz A, Kuhn T, et al
    Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
    Int J Cancer. 2021 Nov 29. doi: 10.1002/ijc.33885.
    >> Share

  45. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    >> Share

    September 2021
  46. XU L, Leng C, Chen L, Dong H, et al
    Hypothyroidism is a Predictive Factor of Superior Anti-tumor Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33813.
    >> Share

    August 2021
  47. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    >> Share

    July 2021
  48. CAO M, Huang W, Chen Y, Li G, et al
    Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through beta-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
    Int J Cancer. 2021;149:460-472.
    >> Share

  49. ZHUO Z, Miao L, Hua W, Chen H, et al
    Genetic variations in nucleotide excision repair (NER) pathway genes and hepatoblastoma susceptibility.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33722.
    >> Share

    June 2021
  50. WANG L, Long J, Chen H, Sun S, et al
    Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis.
    Int J Cancer. 2021;148:2815-2824.
    >> Share

    May 2021
  51. LONG L, Liu X, Jin L, Simon T, et al
    Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men.
    Int J Cancer. 2021 May 24. doi: 10.1002/ijc.33699.
    >> Share

    April 2021
  52. MAYEN AL, Aglago EK, Knaze V, Cordova R, et al
    Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: a multinational cohort study.
    Int J Cancer. 2021 Apr 25. doi: 10.1002/ijc.33612.
    >> Share

  53. LU L, Xing K, Wei W, Ling Y, et al
    Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33609.
    >> Share

  54. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    >> Share

    March 2021
  55. WASHINGTON MK, Goldberg RM, Chang GJ, Limburg P, et al
    Diagnosis of digestive system tumours.
    Int J Cancer. 2021;148:1040-1050.
    >> Share

    November 2020
  56. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    >> Share

  57. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    >> Share

    October 2020
  58. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    >> Share

  59. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    >> Share

    September 2020
  60. FRENCH B, Sadakane A, Cologne J, Mabuchi K, et al
    Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors.
    Int J Cancer. 2020;147:1294-1299.
    >> Share

  61. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    >> Share

    August 2020
  62. ZHONG GC, Wang K, Peng Y, Shivappa N, et al
    Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.
    Int J Cancer. 2020;147:1050-1058.
    >> Share

    July 2020
  63. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    >> Share

    February 2020
  64. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    >> Share

    December 2019
  65. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016